💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Pfizer, Allergan in final stage of merger talks: CNBC

Published 11/19/2015, 09:35 AM
Updated 11/19/2015, 09:40 AM
© Reuters. Sign is seen at the Pfizer manufacturing plant in Newbridge, County Kildare, Ireland
AGN
-
PFE
-

(Reuters) - Pfizer Inc (N:PFE) and Allergan Plc (N:AGN) are in final stages of talks over an all-stock deal, CNBC tweeted, citing sources.

Reuters reported on Wednesday that Pfizer's talks to acquire Allergan had accelerated, as the U.S. Treasury prepares to clamp down further on tax inversions.

Pfizer will offer more than 11 shares for each Allergan share held, CNBC said on Thursday

The offer would value Allergan at at least $366.41 per share, or a total of more than $144 billion.

The deal would result Pfizer to domicile in Ireland.

The Treasury this week will clamp down further on tax-avoiding "inversion" deals done by U.S. companies with foreign rivals, according to a letter obtained by Reuters on Wednesday.

© Reuters. Sign is seen at the Pfizer manufacturing plant in Newbridge, County Kildare, Ireland

Pfizer shares were down 1.6 percent in early trading, while Allergan's were down 1.8 percent.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.